Vardenafil: A novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbits

Journal of Molecular and Cellular Cardiology

Volumn 40, Issue 3, 2006, Pages 405-411

  Salloum, Fadi N ^a   Ockaili, Ramzi A ^a   Wittkamp, Michael ^a   Marwaha, Vijay R ^a   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cGMP; Ischemia reperfusion injury; Myocardial preconditioning; Nitric oxide; Phosphodiesterase inhibitors; PKG; Potassium channels; Vasodilation

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CLAMIKALANT; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; SODIUM CHLORIDE; TETRAZOLIUM; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; STAINING; TISSUE SECTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOTONIC AGENTS; HEMODYNAMIC PROCESSES; IMIDAZOLES; MALE; MITOCHONDRIA, HEART; MYOCARDIAL INFARCTION; PIPERAZINES; POTASSIUM CHANNELS; RABBITS; RANDOM ALLOCATION; REPERFUSION INJURY; SULFONES; TRIAZINES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 33244461488     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2005.10.002     Document Type: Article

References (35)

1. L. Zhao, P.A. Weber, J.R. Smith, M.L. Comerford, and G.T. Elliott Role of inducible nitric oxide synthase in pharmacological "preconditioning" with monophosphoryl lipid A J. Mol. Cell. Cardiol. 29 1997 1567 1576
2. L. Xi, N.C. Jarrett, M.L. Hess, and R.C. Kukreja Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice Circulation 99 1999 2157 2163
3. L. Xi, F. Salloum, D. Tekin, N.C. Jarrett, and R.C. Kukreja Glycolipid RC552 induces delayed preconditioning-like effect via iNOS-dependent pathway in mice Am. J. Physiol. 277 1999 H2418 H2424
4. 1 receptors: evidence from gene-knockout mice Circulation 102 2000 902 907
5. M.I. Tejero-Taldo, E. Gursoy, T.C. Zhao, and R.C. Kukreja α-Adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart J. Mol. Cell. Cardiol. 34 2002 185 195
6. T.C. Zhao, M.M. Taher, K.C. Valerie, and R.C. Kukreja p38 triggers late preconditioning elicited by anisomycin in heart: involvement of NF-kB and iNOS Circ. Res. 89 2001 915 922
7. E. Gursoy, T.C. Zhao, M.I. Tajero-Taldo, and R.C. Kukreja Absence of delayed cardioprotective effect of mitochondrial KATP channel opener, diazoxide in mice with targeted ablation of inducible nitric oxide synthase gene Circulation 101 Suppl 2001 (II-263)
8. J. Ahlner, R.G.G. Andersson, K. Torfgard, and X.L. Axelsson Organic nitrate esters: clinical use and mechanisms of actions Pharmacol. Rev. 43 1991 351 423
9. R.R. Fiscus Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells Neurosignals 11 2002 175 190
10. H.R. Weiss, E. Rodriguez, J. Tse, and P.M. Scholz Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts Clin. Exp. Pharmacol. Physiol. 21 1994 607 614
11. E. Kodani, Y.T. Xuan, H. Takano, K. Shinmura, X.L. Tang, and R. Bolli Role of cyclic guanosine monophosphate in late preconditioning in conscious rabbits Circulation 105 2002 3046 3052
12. ATP channels in rabbits Am. J. Physiol. 283 2002 H1263 H1269
13. A. Das, R. Ockaili, F. Salloum, and R.C. Kukreja Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits Am. J. Physiol. 286 2004 H1455 H1460
14. F. Salloum, L. Xi, R. Ockaili, C. Yin, and R.C. Kukreja Delayed pharmacological preconditioning with Viagra (Sildenafil) against myocardial infarction is independent of p38 MAPK signaling pathway Circulation 106 Suppl. 2002 378
15. F. Salloum, C. Yin, L. Xi, and R.C. Kukreja Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart Circ. Res. 94 2003 595 597
16. A. Das, L. Xi, and R.C. Kukreja Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling J. Biol. Chem. 280 2005 12944 12955
17. S. Choi, L. O'Connell, K. Min, N.N. Kim, R. Munarriz, and I. Goldstein Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model J. Androl. 23 2002 332 337
18. H. Porst, R. Rosen, H. Padma-Nathan, I. Goldstein, F. Giuliano, and E. Ulbrich The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial Int. J. Impot. Res. 13 2001 192 199
19. I. Eardley, and J. Cartledge Tadalafil (Cialis) for men with erectile dysfunction Int. J. Clin. Pract. 56 2002 300 304
20. K.I. Yoshida, M.M. Maaieh, J.B. Shipley, M. Doloresco, N.L. Bernardo, and Y.Z. Qian Monophosphoryl lipid A induces pharmacologic " preconditioning" in rabbit hearts without concomitant expression of 70:kDa heat shock protein Mol. Cell. Biochem. 156 1996 1 8
21. N.L. Bernardo, M. D'Angelo, S. Okubo, A. Joy, and R.C. Kukreja Delayed ischemic preconditioning is mediated by opening of ATP-sensitive potassium channels in the rabbit heart Am. J. Physiol. 276 1999 H1323 H1330
22. ATP channel induces early and delayed cardioprotective effect: role of nitric oxide Am. J. Physiol. 277 1999 H2425 H2434
23. J.D. Corbin, and S.H. Francis Cyclic GMP phosphodiesterase-5: target of sildenafil J. Biol. Chem. 274 1999 13729 13732
24. E. Bischoff Potency, selectivity, and consequences of nonselectivity of PDE inhibition Int. J. Impot. Res. 16 2004 S11 S14
25. H. Senzaki, C.J. Smith, G.J. Juang, T. Isoda, S.P. Mayer, and A. Ohler Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure FASEB J. 15 2001 1718 1726
26. K. Loughney, T.R. Hill, V.A. Florio, L. Uher, G.J. Rosman, and S.L. Wolda Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase Gene 216 1998 139 147
27. M. Ito, M. Nishikawa, M. Fujioka, M. Miyahara, N. Isaka, and H. Shiku Characterization of the isoenzymes of cyclic nucleotide phosphodiesterase in human platelets and the effects of E4021 Cell. Signal. 8 1996 575 581
28. R.M. Wallis, J.D. Corbin, S.H. Francis, and P. Ellis Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro Am. J. Cardiol 83 1999 (3C-12C 21)
29. J. Pryor Vardenafil: update on clinical experience Int. J. Impot. Res. 1 Suppl 2002 S65 S69
30. R.C. Kukreja, F. Salloum, A. Das, R. Ockaili, C. Yin, and Y.A. Bremer Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications Vasc. Pharmacol. 42 2005 219 232
31. E.F. du Toit, E. Rossouw, R. Salie, L.H. Opie, and A. Lochner Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model Cardiovasc. Drugs Ther. 19 2005 23 31
32. ATP channel. presented at the AHA symposium on "Targeting Heart Failure: New Tools, New Science and New Strategies, at Keystone", CO. July 24-27, 2005.
33. A.D. Costa, K.D. Garlid, I.C. West, T.M. Lincoln, J.M. Downey, M.V. Cohen, and S.D. Critz Protein kinase G transmits the cardioprotective signal from cytosol to mitochondria Circ. Res. 97 2005 329 336 (Epub 2005 Jul 21)
34. Product monograph for Levitra (vardenafil HCL). Bayer Health Care, Glaxo SmithKline; 2003.
35. S.M. Auerbach, M. Gittelman, A. Mazzu, F. Cihon, P. Sundaresan, and W.B. White Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia Urology 64 2004 998 1003